INS and type 1 diabetes mellitus: The main outcome measures were Life Expectancy, Quality adjusted life years (QALYs), Total Costs and Incremental Costs and Effectiveness Ratio (ICER) of CSII compared with MDI in Chinese pediatric patients with T1DM in Qingdao City (60 years).<h4>Results</h4>Mean HbA1c values and daily insulin doses were significantly lower in those receiving CSII therapy throughout follow-up.